ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have received a consensus recommendation of “Moderate Buy” from the nine analysts that are presently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $105.00.

A number of equities analysts have commented on the stock. Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Weiss Ratings raised shares of ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, June 23rd. Guggenheim restated a “buy” rating and set a $124.00 price target on shares of ANI Pharmaceuticals in a report on Friday, July 10th. Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Finally, Canaccord Genuity Group initiated coverage on ANI Pharmaceuticals in a report on Thursday, July 16th. They issued a “hold” rating and a $91.00 price objective on the stock.

Insider Buying and Selling

In other news, CFO Stephen P. Carey sold 3,313 shares of the stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $86.00, for a total transaction of $284,918.00. Following the completion of the transaction, the chief financial officer directly owned 177,543 shares in the company, valued at approximately $15,268,698. This represents a 1.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Meredith Cook sold 500 shares of the firm’s stock in a transaction dated Monday, July 13th. The stock was sold at an average price of $81.84, for a total value of $40,920.00. Following the sale, the vice president directly owned 77,390 shares of the company’s stock, valued at $6,333,597.60. The trade was a 0.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 85,179 shares of company stock valued at $6,722,596. 8.10% of the stock is currently owned by company insiders.

Institutional Trading of ANI Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the stock. KBC Group NV acquired a new position in ANI Pharmaceuticals in the first quarter valued at about $28,000. Advisors Asset Management Inc. acquired a new stake in shares of ANI Pharmaceuticals during the first quarter valued at about $28,000. Hantz Financial Services Inc. increased its position in shares of ANI Pharmaceuticals by 70.3% during the fourth quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock valued at $48,000 after acquiring an additional 249 shares during the last quarter. Kemnay Advisory Services Inc. purchased a new stake in shares of ANI Pharmaceuticals in the 4th quarter valued at approximately $48,000. Finally, State of Wyoming purchased a new stake in shares of ANI Pharmaceuticals in the 2nd quarter valued at approximately $50,000. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Stock Down 1.1%

Shares of ANIP opened at $77.65 on Friday. ANI Pharmaceuticals has a 52-week low of $62.60 and a 52-week high of $99.50. The company has a quick ratio of 2.52, a current ratio of 3.12 and a debt-to-equity ratio of 1.06. The stock has a fifty day simple moving average of $81.26 and a two-hundred day simple moving average of $79.47. The company has a market capitalization of $1.77 billion, a PE ratio of 19.66 and a beta of 0.43.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.77. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The firm had revenue of $237.46 million for the quarter, compared to analysts’ expectations of $207.63 million. During the same quarter in the previous year, the company posted $1.70 EPS. The company’s revenue was up 20.5% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, equities analysts forecast that ANI Pharmaceuticals will post 8.03 EPS for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.